Plain-English translation of NCT06454968 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a three-drug combination called the OGL regimen—which includes orelabrutinib, obinutuzumab, and lenalidomide—can safely and effectively treat marginal zone lymphoma in patients who have never been treated before. You would receive six cycles of all three medications together, and if your cancer responds well, you would then continue with orelabrutinib alone for six more cycles. The goal is to see if this combination helps more patients achieve long-lasting remission.
Marginal zone lymphoma is a type of blood cancer that usually progresses slowly, but some patients still face serious problems like the cancer coming back or transforming into a more aggressive form. Researchers want to test whether this medication combination can improve outcomes and help prevent these complications in people newly diagnosed with this disease.
You likely qualify if…
You likely don't qualify if…
You would receive six cycles (rounds) of treatment with all three medications combined, where each cycle lasts about 3–4 weeks. You would take orelabrutinib by mouth daily, receive obinutuzumab as an intravenous infusion, and take lenalidomide by mouth for the first two weeks of each cycle. After six cycles, if your cancer responds well, you would continue taking orelabrutinib alone for six more cycles. Throughout the trial, you would have regular doctor visits, blood tests, and imaging scans to monitor how well the treatment is working and to watch for any side effects.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China